AI주식인사이트AI Stock Insight
B

드림씨아이에스

223250KOSDAQ자연과학 및 공학 연구개발업

62.0 / 100

Reference Date: 2026-04-13

Financial Score33.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers and PBR is significantly undervalued vs. peers is also solid. Declined 8.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

DreamCIS is a Contract Research Organization (CRO) that provides comprehensive services such as clinical trial design, data management, statistical analysis, and regulatory submissions for pharmaceutical companies. With over 25 years of experience and global expansion, the company is addressing growing demand for high-value drug development, including gene therapies and next-generation treatments.

Number of Employees

395people

Average Salary

55.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
15.77Industry Average 120.078.0Point

Half of industry avg (excellent)

PBR
1.35Industry Average 3.827.0Point

Half of industry avg (excellent)

ROE
9.25Industry Average -32.113.5Point

Well below industry avg

Debt Ratio
2.75Industry Average 7.526.5Point

Half of industry avg (excellent)

Trend 2023~20258.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲18.1% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲111.0% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 8.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (38%)

Current 4,715Won52-week high 7,69052-week low 2,870
1-month return1.0Point

1m -8.45% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-06
  • Neutral정기주주총회결과2026-03-31
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
  • Neutral[기재정정]주주총회소집공고2026-03-24
  • Neutral파생상품거래손실발생2026-03-24